AUTHOR INDEX

VOLUME 51

Aasted, Bent., 7
Abraham, Gordon, 340
Ahmed, Rafi, 34
Ahola, Harri, 872
Akkina, Ramesh K., 395
Anderson, Carl W., 559
Anderson, Mary E., 91
Anderson, Soni J., 730
Angermüller, Sieglinde, 452
Appel, Max J. G., 643
Arbeter, Allan M., 110

Baba, Timothy W., 123
Babiuk, Lorne A., 489
Balachandran, N., 263
Banerjee, Amiya K., 628
Bång, Barbro, 137
Bastin, Marcel, 242
Battles, Jane K., 880
Baxt, Barry, 298
Bean, W. J., 863
Bedigian, Hendrick G., 586
Bellamy, A. Richard, 97
Benavente, Javier, 866
Benjamin, David C., 272
Bergmann, I. E., 799
Berk, Arnold J., 884
Berns, Kenneth I., 329
Bestwick, Richard K., 695
Bienenstock, John, 747
Bloom, Barry R., 845
Bloom, Marshall E., 7
Bodemer, Walter, 452
Bonneaud, Nathalie, 530
Boone, Thomas, 20
Boring, John W., 52
Bornkamm, Georg W., 199
Boswell, Bruce A., 695
Both, Gerald W., 97
Brais, J., 747
Bratt, Michael A., 81, 445
Bream, Gary L., 458
Brian, David A., 384
Brotman, Betsy, 420
Brown, Jay C., 52
Butel, Janet S., 376
Byrne, Jacquelyn A., 34, 682

Cachianes, George, 571
Campadelli-Fiume, Gabriella, 838
Cannella, Maria T., 458
Carr, Anthony, 170
Carter, Barrie J., 611
Chambers, Thomas M., 395
Champoux, James J., 26
Chen, S. S., 14
Chesebro, Bruce, 63
Cho, Myung-Sam, 199
Clark, H. Fred, 233
Clements, Janice E., 713
Cohen, Gary L., 91
Collins, Lisa, 788
Colonno, Richard J., 340
Copeland, Neal G., 586
Costa, R. H., 578
Cowie, Alison, 170
Crawford, Robert, 776
Croissant, Odile, 530
Cywinski, Anita, 267

Dall'Olio, Fabio, 838
Davis, Robert L., 223
De, Bishnu P., 628
DeLucia, Angelo L., 91
De Mello, P. Augé, 799
Dodd, Wendell K., 425
Doermann, A. H., 315
Douglas, Steven D., 110
Draper, K. G., 578

Early, G., 863
Ebihara, Kazumasa, 117
Edery, Isaac, 832
Egan, John E., 845
Ehrenfeld, Ellie, 832
Ely, Constance M., 272
Esteban, Mariano, 866
Etchison, Diane, 832
Evans, Leonard, 63
Evans, Robert, 586

Faras, Anthony J., 813
Fennewald, Susan, 411
Finston, Wendi I., 26
Fiorelli, P., 863
Fitzgerald, David J. P., 650
Fleckenstein, Bernhard, 452
Folk, William R., 437
Frenkel, Niza, 595
Frisque, Richard J., 458
Fritsch, Sandra L., 259
Fukuchi, Kunihiko, 102
Furuichi, Y., 856
Furuichi, Yasuhiro, 97, 860

Ganem, Don, 367
Garcia, Pablo D., 776
Garon, Claude F., 131
Gelinas, Celine, 242
Gentry, Larry E., 539
Georges, Elisabeth, 530
Geraci, J. R., 863
Gerwin, Brenda I., 470
Gilardi, Pascale, 822
Gilden Donald H., 563
Giomi, M. P. Costa, 799
Gomez, I., 799
Gonda, Matthew A., 306, 730
Greenlee, John E., 425
Guidolin, Angelo, 163

Hackett, Perry B., 722
Hall, William W., 643
Hampar, Berge, 430
Hankins, W. David, 247
Hansen, Joanna, 832
Harada, Fumio, 154
Harmison, George G., 505, 515
Hartley, Janet W., 77
Harvey, Robert, 670
Hashimoto, K., 254
Haus, Margret, 795
Hay, John, 237
Hensel, Charles H., 722
Hermonat, Paul L., 329
Herr, Lori L., 259
Hershey, John W. B., 832
Highkin, Maureen K., 563
Hinshaw, V. S., 863
Hinshaw, Virginia S., 567
Hogue, Brenda G., 384
Hruby, Dennis E., 359
Hsu, Henry, 776
Hsu, M.-T., 14
Hu, Shiu-Lok, 880
Hu, Stella C., 470
Humphries, Eric H., 123
Hurme, Mikko, 137

Ihara, Toshiaki, 110
Ikegami, N., 856
Ikegami, Nobuko, 97, 860
Iorio, Ronald M., 445
Ito, Masahiro, 110
Iwamoto, Aikichi, 860

Jabbar, M. Abdul, 522
Jenkins, Nancy A., 586
Johnson, David A., 586
Johnson, David C., 389

Kabat, David, 695
Kamen, Robert, 170
Kaminchick, Joseph, 247, 306
Kamke, Marion, 163
Kawai, Sadaaki, 147, 154
Keene, Jack D., 515
Kieff, Elliott, 411
King, Bernadette, 384
Knust, Elisabeth, 452
Konopka, James B., 223
Kornstein, M. J., 233
Koyama, Takumi, 147, 154
Kozak, Christine A., 77, 876
Kress, Yvonne, 845
Kuismanen, Esa, 137, 806
Kwong, Ann D., 595

Labow, Mark A., 329
Lambert, Jean-Pierre, 47
Lane, David P., 760
Lang, Dimitrij, 479, 484
Last-Barney, Kathleen, 20
La Torre, J. L., 799
Lausch, Robert N., 656
Lavi, Ehud, 563
Lee, Elsbeth J., 247
Lee, G. T.-Y., 578
Lee, Yih-Shong, 102
Lefrancois, Leo, 208
Lemieux, Réal, 215
LeMoullec, Jean Michel, 822
Leslie, P., 747
Levin, Judith G., 470
Lewton, Betsy A., 91
Lindberg, Michael, 742

Maes, Roger K., 259
Magnusson, Göran, 768
Manning, Paul A., 163
Marbehant, Pol, 47
Marchin, George L., 42
Marissens, Denise, 47
Mason, William S., 181
Masse, Serge, 242
McCarley, Deborah J., 272
McCulley, James P., 556
McDermott, Mark R., 747
McLear, Patrick W., 635
Meier, Ellen, 505, 515
Mendelson, Stuart G., 643
Menke, John, 306
Merluzzi, Vincent J., 20
Mertelsmann, Roland H., 20
Messer, Lesley I., 470
Milburn, Susan, 832
Miller, Irving L., 611
Millward, Stewart, 215
Minamishima, Yoichi, 117
Miyamura, Kikuko, 192
Molineaux, Susan M., 713
Molnar-Kimber, Katherine L., 181
Montano, Ximena, 760
Morelli, Giovanna, 163
Moreno-Lopez, Jorge, 872
Morgan, Donald O., 298
Morgan, Jeffrey R., 283
Morrison, T., 71
Morse, Herbert C., III, 77
Moss, Bernard, 662
Munz, Patricia, 571
Muzyczka, Nicholas, 329

Naeve, Clayton W., 567
Nagashima, Kunio, 306
Najita, L. M., 547
Nakamura, Gerald R., 346
Narayan, Opendra, 713
Näslund, Anders, 822
Nasseri, Mohammad, 706
Nayak, Debi P., 395
Newcomb, William W., 52
Niederkorn, Jerry Y., 556
Nilsson, Stefan V., 768
Nishio, Jane, 63
Nomoto, A., 856
Nomoto, Akio, 860
Nonoyama, Meihan, 102

Oakes, John E., 656
Offit, Paul A., 233
Ogata, T., 254
Ohnishi, Shun-Ichi, 497
Okada, Y., 856
Oker-Blom, Christian, 354
Oldstone, Michael B. A., 34, 682
Oliff, Allen, 306, 788
Olson, Norma J., 42
Omer, Charles A., 813
Orth, Gérard, 530
Osterhaus, Albert, 872

Paez, Eduardo, 866
Parsons, J. Thomas, 272
Parsons, Sarah J., 272
Pastan, Ira, 650
Patzer, Eric J., 346
Paucha, Eva, 670
Peeples, Mark E., 81
Pereira, Lenore, 838
Perrault, Jacques, 635
Perricaudet, Michel, 822
Persson, Robert, 687
Petersen, Robert B., 722
Petre, Jean, 754
Pettersson, Ralf F., 137

Pettersson, Ulf, 742, 822, 872
Plotkin, Stanley A., 233
Ponticelli, Alfred S., 223
Potts, Diane E., 880
Prakash, Om, 604
Prince, Alfred M., 420
Purdy, Michael, 754
Pyper, Joanna M., 713

Race, Richard E., 7
Racevskis, Janis, 604
Rager-Zisman, Bracha, 845
Randolph, Barbara, 321
Rawls, William E., 263
Rehg, J. E., 863
Rein, Alan, 470
Reinhold, William, 131
Resnick, Robert, 813
Rettenmier, Carl W., 730
Rhoades, Marc, 553
Richardson, M. A., 856
Richardson, Michael A., 860
Richardson, William D., 404, 559
Roberts, Bryan E., 283
Robertson, Betty H., 298
Rohrschneider, Larry R., 539
Rohrschneider, L. R., 547
Roseman, Nancy A., 359
Rosenberg, Naomi, 223
Rosenberg, Naomi E., 620
Rota, Paul A., 259
Roy, Polly, 754
Rudzroga, Helen E., 747
Rueckert, Roland R., 251
Rutter, William J., 776

Sabara, Marta, 489
Santos, Myriam, 376
Schaffhausen, Brian, 170
Schiff-Maker, Leslie, 223
Schubert, Manfred, 505, 515
Scodeller, E. A., 799
Scolnick, Edward M., 306
Seeger, Christoph, 367
Selling, Bernard H., 251
Serafini-Cessi, Franca, 838
Seth, Prem, 650
Shatkin, Aaron J., 97
Shaul, Yosef, 776
Sherr, Charles J., 730
Showalter, Stephen D., 430
Siegman, Linda J., 97
Signorelli, Kathy, 788
Silverstein, Saul, 571
Simizu, B., 254
Simms, Donald J., 430
Simon, Lee D., 315, 321
Sisson, Gary, 263
Smiley, James R., 747
Smith, Alan E., 670
Snyder, Larry, 522
Soeda, Eiichi, 1
Sonenberg, Nahum, 832
Souza, Lawrence, 20
Spear, Patricia G., 389
Spear, P. G., 578
Spindler, Katherine R., 884
Stålhandske, Per O. K., 742
St. Aubin, D. J., 863
Starr, Stuart E., 110
Steely, H. Thomas, Jr., 479
Stenlund, Arne, 872
Stephan, Wolfgang, 420
Straus, Stephen E., 131
Streilein, J. Wayne, 556
Sudo, Miyuki, 102
Summers, Jesse W., 181
Svensson, Ulla, 687

Takeda, Naokazu, 192
Takiff, Howard E., 131
Tanaka, Akiko, 102
Taylor, John M., 267
Tegtmeyer, Peter, 91
Timpone, Charles A., 298
Tratschin, Jon-Duri, 611
Triezenberg, Steven J., 437

Uchida, Seijiro, 1

Valenzuela, Pablo, 776
van Santen, Vicky, 411
Varmus, Harold E., 367
Veldman, Geertruida M., 170
Villarreal, Elcira C., 359
Virtanen, Anders, 822

Wagner, E. K., 578
Watanabe, Sumie, 1
Watanabe, Susan M., 223, 620
Wathen, Lynne M. K., 57
Wathen, Michael W., 57, 237
Watson, Roger J., 263
Webster, R. G., 863
Webster, Robert G., 567
Wehrly, Kathy, 63
Weir, Jerry P., 662
Weiss, Susan R., 563
Welte, Karl, 20
Westphal, Heiner, 404
Wettstein, Felix O., 706
Whittum, Judith A., 556
Wilde, A., 71
Willingham, Mark C., 650
Wilmes, Eberhard, 795
Witte, Owen N., 223, 620
Wolf, Hans, 795
Wright, Peter J., 91
Wright, Richard, 329

Yaffe, Avima, 346
Yamamoto, K., 254
Yamazaki, Shudo, 192
Yang, Young, 484
Yoshiike, Kunito, 1
Yoshimura, Akihiko, 497
Young, C. S. H., 571

Zarbl, Helmut, 215
Zhu, Zuoyan, 170
Ziemer, Marilyn, 776
Zissis, Georges, 47
zur Hausen, Harald, 199
Zweig, Martin, 430

SUBJECT INDEX

VOLUME 51

Abelson murine leukemia virus
  kinase activity
    v-*abl* protein *src* homologous region, 223
  L-v-*abl* protein, 620
  v-*abl* gene product in transformed cells, 547
  v-*abl* protein
    phosphorylation, 620
Adeno-associated virus
  adenovirus helper effect
    early region 1a or 1b requirement, 404
  deletion mutants constructed in vitro, 611
  genetic analysis, 611
  helper effect
    adenovirus early region 1a or 1b requirement, 404
  replication function evidence, 611
  type 2 mutant
    isolation and preliminary characterization, 329
Adenovirus 2
  core structure, 53
  early region 4 mRNAs, 822
  entry into HeLa cells, 687
  HeLa cell entry, 687
  ion etching, 53
  mRNA, late
    translation in African green monkey kidney cells, 559
  Pseudomonas exotoxin-epidermal growth factor conjugate toxicity
    low-pH environment, 650
Adenovirus 7
  homology
    adenovirus 2, 880
    adenovirus 3, 880
  restriction analysis, 880
Adenovirus early region 1A
  5′ untranslated region
    translation efficiency of deletion mutants, 884
Adenoviruses
  enteric
    candidate types 40 and 41, 131
  helper effect for adeno-associated virus
    early region 1a or 1b requirement, 404
  recombination, 571
  replication, 571
  replication and recombination in infected cells
    functional relationship, 571
    temporal relationship, 571
African green monkey kidney cells
  adenovirus 2 late mRNA translation, 559
Akv-2
  hamster-mouse hybrid cells
    ecotropic murine leukemia virus expression, 876
Aleutian disease virus
  mink
    proteolytic degradation, 7
Alexander cells
  integrated HBV sequences, 776
Amplicon
  eucaryotic DNA, 595
  herpes simplex virus
    replication of genomes with eucaryotic DNA, 595
Aphthovirus
  polyribocytidylic acid tract
    length variation, 799
ATP
  vesicular stomatitis virus transcription dependence, 635
Avian influenza virus
  hemagglutinin receptor-binding site mutation
    biological property change, 567
  isolation from seals, 863
  reassortants containing human hemagglutinin, 567
Avian leukosis virus
  chickens
    DNA integration, 123
    FP line, 123
    SC line, 123
    viremia, 123

Bacteriophage CP-T1
  DNA characterization and restriction analysis, 163
  V. cholerae, 163
Bacteriophage ϕ6
  electron microscopy of nucleocapsid
    three-dimensional image analysis, 484
    two-dimensional image analysis, 479
  nucleocapsid structure, 479, 484
Bacteriophage T4
  bypass31 mutations
    isolation and characterization, 321
    mapping by UV rescue, 315
  E. coli restriction locus analysis, 522
  gene 31, 315, 321
  polynucleotide kinase- and RNA ligase-deficient mutants
    restriction by an *E. coli* locus, 522
  valyl-tRNA synthetase restriction, 42
Bacteriophage T5
  single-chain interruption mutant, 553
Biological response modifiers
  protective effect
    cytomegalovirus infection, 117
BK virus
  DNA rearrangement
    transforming gene expression, effect on, 1
Black beetle virus
  plaque assay, 251
Bluetongue virus
  L3 gene cloning and sequence, 754
Bovine coronavirus
  human respiratory coronavirus OC43 antigenic relatedness, 384
  mouse hepatitis coronavirus A59 antigenic relatedness, 384
Bovine rotavirus
  cellular attachment, 489
  gene and gene product identification, 489
  segment 10 gene and product
    cellular attachment influence, 489
Bxv-1
  hamster-mouse hybrid cells
    xenotropic murine leukemia virus expression, 876
  xenotropic murine leukemia virus induction, 77
bypass31
  phage T4
    gene 31, 315, 321
    isolation and characterization, 321
    mapping by UV rescue, 315

Canine distemper virus-antibody complexes
  infectivity, 643
  macrophage Fc receptors, 643
  neutralization, 643
Cap-binding protein complex
  inhibition in poliovirus-infected HeLa cells, 832
Caprine arthritis-encephalitis virus
  visna virus homology, 713
Carcinoma cell line
  human hepatoma
    integrated HBV sequences, 776
Cell attachment
  foot-and-mouth disease virus outer capsid protein VP_1
    epitopes, 298
Cell entry
  adenovirus 2 into HeLa cells, 687
Chickens
  avian leukosis virus
    DNA integration, 123
    viremia, 123
  FP line, 123
  SC line, 123
Chikungunya virus
  structural proteins, 255
Clearance
  lymphocytic choriomeningitis virus, 682
Cold-sensitive mutation
  measles virus from neuroblastoma cells, 845
Copy choice replication
  vesicular stomatitis virus defective-interfering particles
    RNA generation sites, 515
Core structure
  human adenovirus 2, 53
  ion etching, 53
Coronaviruses
  antigenic relationships, 384
Cottontail rabbit papillomavirus
  genome physical state
    VX2 carcinoma, 530
    VX7 carcinoma, 530
    warts, 530
  transcription
    VX2 carcinoma, 530
    VX7 carcinoma, 530
    warts, 530
  viral transcript differences among tumors, 706
Coxsackievirus B3
  replicase gene sequence, 742
Cyclophosphamide
  cytotoxic T-lymphocyte response, 20
  mice, 20

Cytomegalovirus
mice
protective effect of biological response modifiers, 117
Cytotoxic T lymphocytes
cloned
lymphocytic choriomeningitis virus clearance, 682
cyclophosphamide suppression, 20
H-2 restricted
lymphocytic choriomeningitis virus clearance, 682
influenza A, 20
interleukin 2 rescue, 20
lymphocytic choriomeningitis virus
H-2 region, 34
recognition among strains, 34
mice, 20
specificity, 34
virus clearance
lymphocytic choriomeningitis virus, 682

DBA/2 mice
xenotropic-like *env* RNA sequence expression, 247
Defective-interfering particles
influenza virus
polypeptide synthesis, 395
polypeptide synthesis in infected cells, 395
vesicular stomatitis virus
RNA generation, 515
Demyelination
mouse hepatitis coronavirus A59
viral persistence, 563
DNA binding
polyomavirus large-T-antigen mutants, 768
DNA integration
avian leukosis virus, 123
DNA mapping
duck hepatitis B virus
cohesive overlap region, 181
reverse transcription initiation site, 181
phage T4 *bypass31* mutations, 315
UV rescue
phage T4 *bypass31* mutations, 315
DNA rearrangement
BK virus transforming gene, 1
DNA recombination
adenoviruses
replication relationship, 571
DNA replication
adeno-associated virus, 611
adenoviruses
recombination relationship, 571
polyoma virus large-T-antigen mutants, 768
DNA supercoil density
SV40
nucleoprotein complex, 15
replicating complex, 15
Dodecahedral virus architecture, 479, 484
Dogs
canine distemper virus
antibody complexes, 643
infectivity, 643
macrophage Fc receptors, 643
neutralization, 643

Duck hepatitis B virus
cohesive overlap region, 181
DNA mapping
cohesive overlap region, 181
reverse transcription initiation site, 181

Early gene cluster
vaccinia virus
RNA transcript organization, 283
Early proteins
polyomavirus
genome construction and functional characterization, 170
Early region 4
adenovirus 2
mRNAs, 822
mRNAs, 822
Early region 1a
adeno-associated virus helper effect role, 404
adenovirus
translation efficiency in deletion mutants, 884
Early region 1b
adeno-associated virus helper effect role, 404
Ecotropic murine leukemia virus
expression in chemically induced hybrid cells, 876
Electron microscopy
bacteriophage ϕ6 nucleocapsid
three-dimensional image analysis, 484
two-dimensional image analysis, 479
Endosomes
influenza virus uncoating, 497
Enteric adenoviruses
candidate types 40 and 41
cloning, 131
physical mapping, 131
Enterovirus 70
elevated temperature, 192
transcription in vitro, 192
env gene
Rauscher spleen focus-forming virus sequence, 695
xenotropic-like RNA sequences
expression in DBA/2 and NZB mice, 247
Epitopes
surface
foot-and-mouth disease virus outer capsid protein VP_1, 298
Epstein-Barr virus
defective DNA, 199
IB4 cell line
nucleotide sequence of a transcribed mRNA, 411
latent infection
mRNA sequence that may encode a membrane protein, 411
parotid gland, 795
persistence in the parotid gland, 795
P3HR-1 cells
DNA structure, 199
Escherichia coli
phage T4 mutant restriction locus analysis, 522
Eucaryotic initiation factor 3
activity in poliovirus-infected HeLa cells, 832

Feline rhinotracheitis virus
immunogenic proteins, 259
Feline sarcoma virus
oncogene, 730
v-*fms*, 730
Fibroblasts, human
varicella-zoster virus infection
polymorphonuclear leukocyte-mediated cytotoxicity, 110
Foot-and-mouth disease virus
outer capsid protein VP_1
epitopes involved in neutralization and cell attachment, 298
polyribocytidylic acid tract
length variation, 799
Friend ecotropic murine leukemia virus
Friend mink cell focus-inducing virus synergy, 63
Friend mink cell focus-forming virus
heteroduplex analysis of molecular clones, 306
Friend mink cell focus-inducing virus
envelope gene
leukemogenesis, 788
FMCF-1-E, 63
Friend ecotropic murine leukemia virus synergy, 63
leukemia induction in mice, 63
leukemogenesis
envelope gene, 788
long terminal repeat, 788
long terminal repeat
leukemogenesis, 788
new strain, 63
Friend murine leukemia virus
envelope gene
leukemogenesis, 788
heteroduplex analysis of molecular clones, 306
leukemogenesis
envelope gene, 788
long terminal repeat, 788
long terminal repeat
leukemogenesis, 788
Friend spleen focus-forming virus
anemia-inducing strains
heteroduplex analysis of molecular clones, 306
polycythemia-inducing strain
heteroduplex analysis of molecular clones, 306
Friend virus complex
heteroduplex analysis, 306
Friend viruses
helper independent
gene sequences in leukemia, 788
Fusion glycoprotein incorporation
Newcastle disease virus matrix protein mutant, 81

Gene expression
regulation
vaccinia virus late gene, 662
Glycoprotein C
HSV-1
antibodies to a synthetic oligopeptide, 430
HSV-2
antibodies to a synthetic oligopeptide, 430

HSV-1 macroplaque strain, 578
Glycoprotein D
HSV-1
translational regulation, 389
HSV-2
type-specific antigenic site, 263
Glycoproteins
HSV-1 gC
processing to mature form, 838
maturation
Uukuniemi virus, 806
pseudorabies virus
antigenically altered gp 50, 57
Goats
caprine arthritis-encephalitis virus
visna virus homology, 713
Ground squirrel hepatitis virus
genome nucleotide sequence, 367
homology with hepatitis B virus and woodchuck hepatitis virus, 367

HeLa cells
adenovirus 2 entry, 687
poliovirus infected
cap-binding protein complex inhibition, 832
eucaryotic initiation factor 3, 832
Hemagglutinin-neuraminidase glycoprotein
Newcastle disease virus
monoclonal antibodies, 445
Hemagglutinin receptor-binding site
mutation in avian influenza virus, 567
Hepatitis B virus
carcinoma
HBV integrated sequences in a human hepatoma cell line, 776
core antigen
modulation of infection, 420
duck
cohesive overlap region DNA map, 181
DNA mapping, 181
reverse transcription initiation site DNA map, 181
e antigen
modulation of infection, 420
integrated sequences
human hepatoma cell line, 776
mammalian cells
surface antigen transport and secretion, 346
modulation of infection
immunoglobulin preparation given intravenously, 420
surface antigen
modulation of infection, 420
transport and secretion in mammalian cells, 346
Hepatoma cell line
human
integrated HBV sequences, 776
Herpes simplex virus
amplicon
replication of genomes with eucaryotic DNA, 595
Herpes simplex virus 2
immunity in female genital tract
intravaginal vaccination in mice, 747
mice
immunity in female genital tract, 747
vaccination
immunity in female genital tract, 747
Herpes simplex virus amplicon
replication of genomes with eucaryotic DNA
effect of size, 595
Herpes simplex virus type 1
deletion clones
HSV-2 *nuc*$^-$ lesion mapping, 237
glycoprotein C
reaction with antibodies to a synthetic oligopeptide, 430
glycoprotein-C-negative phenotype
molecular basis, 578
glycoprotein D
translational regulation, 389
glycoprotein gC
processing of *N*-linked oligosaccharides, 838
immune deviation
suppressor T cell role, 556
macroplaque strain, 578
monoclonal antibodies
replication suppression in trigeminal ganglia, 656
ocular infection
replication suppression by monoclonal antibodies, 656
replication
suppression by monoclonal antibodies in trigeminal ganglia, 656
trigeminal ganglia, 656
translational regulation of glycoprotein D, 389
trigeminal ganglia
replication suppression by monoclonal antibodies, 656
Herpes simplex virus type 2
glycoprotein C
reaction with antibodies to a synthetic oligopeptide, 430
glycoprotein D
type-specific antigenic site, 263
nuc$^-$ lesion
mapping, 237
Herpesvirus saimiri
immediate-early transcription, 452
Heteroduplex analysis
Friend virus complex, 306
Human respiratory coronavirus OC43
bovine coronavirus antigenic relatedness, 384
mouse hepatitis coronavirus A59 antigenic relatedness, 384
Hybrid cells
hamster-mouse
murine leukemia virus expression, 876
H-2 region
lymphocytic choriomeningitis virus
cross-reactivity, 34

Immediate-early transcription
Herpesvirus saimiri, 452
Immune deviation
HSV-1 induced
suppressor T cell role, 556
Immunofluorescence microscopy
monoclonal glycoprotein-specific antibodies, 137
Uukuniemi virus maturation, 137
Immunoglobulin preparation
modulation of hepatitis B virus infection, 420
Immunosuppression
reactivation of papovavirus K infection in mice, 425
Influenza A virus
cytotoxic T-lymphocytes
cyclophosphamide suppression, 20
interleukin 2 rescue, 20
mice, 20
Influenza virus
avian
hemagglutinin receptor-binding site mutation, 567
isolation from seals, 863
defective-interfering particle RNAs
transcription in infected cells, 395
intracellular uncoating, 497
uncoating in endosomes, 497
Interferon
RNA degradation in vaccinia virus-infected mouse L cells, 866
vaccinia virus-infected mouse L cell treatment
RNA degradation, 866
Interleukin 2
cyclophosphamide-treated mice, 20
cytotoxic T-lymphocyte response, 20
Ion etching
human adenovirus 2 core structure, 53

JC virus
genome sequence, 458
protein primary structures, 458

Kinase activity
Abelson murine leukemia virus
v-*abl* protein *src* homologous region, 223

Large-T antigen
antibodies to synthetic peptides, 670
cell surface associated
SV40-infected cells, 376
SV40-transformed cells, 376
immunoprecipitation with antibodies to synthetic peptides, 670
mutant
DNA binding, 768
DNA replication activity, 768
localization, 768
polyomavirus mutants, 768
SV40
cellular protein p53 complex, 376
Latent virus infection
mRNA that may encode a membrane protein
nucleotide sequence, 411
L cells
mouse
RNA degradation in vaccinia virus-infected cells, 866
reovirus infected
mRNA discrimination, 215
Lentiviruses
caprine arthritis-encephalitis virus
visna virus homology, 713

visna virus
caprine arthritis-encephalitis virus homology, 713
Leukemia
BXH mice
induced, 586
spontaneous, 586
Friend viruses
mink cell focus-inducing virus sequences, 788
murine leukemia virus sequences, 788
induced
recombinant inbred BXH mice, 586
induction in mice by Friend mink cell focus-inducing virus, 63
myeloid origin
recombinant inbred BXH mice, 586
spontaneous
recombinant inbred BXH mice, 586
Long terminal repeat
generation
retrovirus reverse transcriptase-associated RNase H, 813
mouse mammary tumor virus
proteins encoded, 604
Rauscher spleen focus-forming virus
sequence, 695
L protein
vesicular stomatitis virus
mRNA synthesis in vitro, 628
ribonucleoprotein template interaction, 628
L-v-*abl* protein
nonphosphorylated, 620
Lymphocytic choriomeningitis virus
clearance
H-2-restricted cytotoxic T lymphocytes, 682
cytotoxic T lymphocytes
H-2 region, 34
recognition among strains, 34
virus clearance in vivo, 682
H-2-restricted cytotoxic T lymphocytes
virus clearance in vivo, 682

Macroplaque strain
HSV-1 glycoprotein-C-negative phenotype
molecular basis, 578
Marek's disease virus
DNA restriction map, 102
Matrix protein
fusion glycoprotein incorporation, 81
Newcastle disease virus, 81
Measles virus
cold-sensitive mutant, 845
Edmonston strain, 845
neuroblastoma cells
cold-sensitive mutant isolation, 845
Mice
BXH
leukemias of myeloid origin, 586
recombinant inbred, 586
Bxv-1, 77
cytomegalovirus
protective effect of biological response modifiers, 117
DBA/2
xenotropic-like *env* RNA sequence expression, 247
HSV-2
intravaginal vaccination, 747
immunosuppression
reactivation of papovavirus K infection, 425
leukemia induction by Friend mink cell focus-inducing virus, 63
MA/My, 77
Mxv-1, 77
NZB, 77
xenotropic-like *env* RNA sequence expression, 247
papovavirus K
reactivation of persistent infection in immunosuppressed mice, 425
recombinant inbred BXH
leukemias of myeloid origin, 586
rotavirus
model for oral infection, 233
vaccination
immunity in female genital tract, 747
xenotropic murine leukemia virus
loci for induction, 77
Middle T protein
polyomavirus, 242
Mink
Aleutian disease virus, 7
Molecular cloning
bluetongue virus L3 gene, 754
coxsackievirus B3 replicase gene, 742
Moloney murine leukemia virus
RNA-primed initiation of plus strand, 26
Monoclonal antibodies
HSV-1 replication suppression, 656
immunofluorescence microscopy, 137
neutralizing
mechanism of action in vivo, 208
Newcastle disease virus hemagglutinin-neuraminidase glycoprotein, 445
nonneutralizing
mechanism of action in vivo, 208
protection against vesicular stomatitis virus infection, 208
rotavirus, 47
Rous sarcoma virus pp60^{src}, 272
small t of SV40, 760
SV40 small t, 760
trigeminal ganglia
HSV-1 replication suppression, 656
Uukuniemi virus glycoprotein specific, 137
vesicular stomatitis virus, 208
Mononucleosis
Epstein-Barr virus
persistence in the parotid gland, 795
Mouse hepatitis coronavirus A59
bovine coronavirus antigenic relatedness, 384
human respiratory coronavirus OC43 antigenic relatedness, 384
persistence of RNA in a slow virus demyelinating infection, 563
Mouse L cells
vaccinia virus infected
RNA degradation on interferon treatment, 866
Mouse mammary tumor virus
long terminal repeat
proteins encoded, 604
mRNA discrimination
L-cells, 215
reovirus-infected L-cells, 215
Murine leukemia virus
expression in chemically induced hybrid cells, 876
clone 23 *pol* mutant
frameshift implications for *pol*, 470
frameshift mutant clone 23, 470
pol mutant clone 23
frameshift implications for *pol*, 470
xenotropic
loci for induction, 77
Mxv-1
xenotropic murine leukemia virus induction, 77
Myeloid leukemia
recombinant inbred BXH mice, 586

Neuroblastoma cells
mouse
measles virus cold-sensitive mutant, 845
Newcastle disease virus
matrix protein mutant
fusion glycoprotein incorporation, 81
infectivity, 81
monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein, 445
neutralization
monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein, 445
requirement for antibodies to four sites, 445
polycistronic RNA species characterization, 71
NS protein
vesicular stomatitis virus
mRNA synthesis in vitro, 628
ribonucleoprotein template interaction, 628
Nucleocapsid protein
vesicular stomatitis
RNA synthesis role, 635
Nucleocapsid structure
bacteriophage ϕ6
three-dimensional image analysis, 484
two-dimensional image analysis, 479
Nucleoprotein complex
density variation, 15
SV40, 15
nuc$^-$ lesion
HSV-2
mapping, 237
NZB mice
xenotropic-like *env* RNA sequence expression, 247

Oligosaccharides
HSV-1 gC
processing of *N*-linked forms, 838
Oncogenes
v-*fms* glycoprotein localization, 730
Oral infection
rotavirus
mouse model, 233
Origin of replication
SV40
spatial requirement in, 91

Packaging mutant
RSV mutant TK15, 147, 154
Papillomavirus
avian

genome map, 872
cottontail rabbit
viral transcript differences among tumors, 706
FPV, 872
Shope
viral transcript differences among tumors, 706
Papovavirus K
reactivation of persistent infection in immunosuppressed mice, 425
Parvoviruses
Aleutian disease virus, 7
mink, 7
proteolytic degradation, 7
pH
adenovirus 2
Pseudomonas exotoxin-epidermal growth factor conjugate toxicity, 650
Phage-host interaction
new phenotypes, 522
P3HR-1 cells
Epstein-Barr virus DNA structure, 199
Plaque assay
black beetle virus, 251
Plus-strand priming
Moloney murine leukemia virus, 26
pol gene
frameshift
murine leukemia virus clone 23, 470
murine leukemia virus
implications of frameshift in clone 23, 470
Poliovirus
cap-binding protein complex inhibition, 832
eucaryotic initiation factor 3, 832
Polycistronic RNA species
Newcastle disease virus, 71
Polymorphonuclear leukocytes
varicella-zoster-infected human fibroblasts, 110
Polyomavirus
early proteins
genome construction and functional characterization, 170
large-T-antigen mutants, 768
middle T protein, 242
mlt mutation, 242
origin mutants, 437
origin region
essential nucleotides, 437
T proteins, 170
genome construction and functional characterization, 170
Polyomavirus JC
genome sequence, 458
protein primary structures, 458
Polyribocytidylic acid tract
length variation in foot-and-mouth disease virus, 799
pp60^{src}
cellular
reaction with Rous sarcoma virus pp60^{src} monoclonal antibodies, 272
Rous sarcoma virus
monoclonal antibodies, 272
Protein synthesis
initiation
Rous sarcoma virus RNA, 722
Pseudomonas exotoxin-epidermal growth factor conjugate
adenovirus 2
enhancement of toxicity at low pH, 650
toxicity
adenovirus 2 enhancement at low pH, 650
Pseudorabies virus
gp50
antigenically altered, 57

Rabbits
cottontail rabbit papillomavirus genome in tumors, 530
Rauscher spleen focus-forming virus
env gene sequence, 695
Friend spleen focus-forming virus sequence comparison, 695
long terminal repeat sequence, 695
molecular clone
env gene sequence, 695
long terminal repeat sequence, 695
Reovirus
L-cells
mRNA discrimination, 215
mRNA discrimination, 215
Replicase
coxsackievirus B3 gene, 742
Replicating complex
density, increased, 15
SV40, 15
Replication
vaccinia virus α-27 mutant
replication independent of the host cell nucleus, 359
Replication function
adeno-associated virus, 611
Replication origin
SV40
spatial requirement in, 91
Restriction mapping
Marek's disease virus DNA, 102
Retroviruses
defective particle (SE21Q1b)
reverse transcription, 267
SE21Q1b
reverse transcription, 267
Retrovirus reverse transcriptase-associated RNase H, 813
Reverse transcriptase
M-MuLV
RNA-primed initiation of plus strand, 26
Reverse transcription initiation site
Duck hepatitis B virus, 181
Rhinovirus
cellular receptor and serotypes, 340
Ribonucleoprotein template
vesicular stomatitis virus
L protein interaction, 628
mRNA synthesis, 628
NS protein interaction, 628
Ribosome binding
leader peptide encoded by Rous sarcoma virus RNA, 722
Rous sarcoma virus RNA, 722
RNA primers
Moloney murine leukemia virus plus-strand initiation, 26
RNase H
retrovirus reverse transcriptase-associated
initiation of strong-stop (+) DNA synthesis, 813
long terminal repeat generation, 813
RNA sequencing
coxsackievirus B3 replicase gene, 742
RNA transcript organization
vaccinia virus early gene cluster, 283
Rotaviruses
bovine
cellular attachment, 489
segment 10 gene and product, 489
human
glycosylated virus protein from segment 10, 856
segment 10 nucleotide sequence, 856
segment 9 nucleotide sequence, 860
serotype-specific antigen sequence, 860
simian SA11 comparison, 860
UK bovine comparison, 860
monoclonal antibodies, 47
mouse model of oral infection, 233
oral infection, 233
simian 11
segment 6, 97
subgroup gene sequences, 97
Wa
segment 6, 97
Rotavirus Wa
glycosylated virus protein from segment 10, 856
segment 10 nucleotide sequence, 856
serotype-specific gene sequence
simian SA11 homologous gene comparison, 860
UK bovine homologous gene comparison, 860
Rous sarcoma virus
leader peptide
ribosome-binding site, 722
monoclonal antibodies to pp60^{src}, 272
mutant TK15
biochemical properties, 154
biological properties, 147
mutant TK15-induced transformants
biochemical properties, 154
biological properties, 147
packaging mutant, 147, 154
pp60^{src} monoclonal antibodies, 272
Rubella virus
structural protein gene order, 354

Sarcomas
yes and *src* gene product common features, 539
Seals
avian influenza virus isolation, 863
SE21Q1b retrovirus
reverse transcription with tRNA-like primers, 267
Sheep
visna virus
caprine arthritis-encephalitis virus homology, 713
Shope papillomavirus
viral transcript differences among tumors, 706
Simian virus 40
antibodies raised to synthetic peptides, 670
large-T antigen
antigenic structure, 376

cellular protein p53 association, 376
immunoprecipitation with antibodies to synthetic peptides, 670
nucleoprotein complexes
supercoil density variation, 15
origin of replication
spatial requirement, 91
replicating complexes
supercoil density, higher, 15
small t monoclonal antibody, 760
transformed cells
large-T antigen–cellular protein p53 complex, 376
Simian virus 40-transformed cells
large-T antigen–cellular protein p53 complex, 376
Small t
SV40
monoclonal antibodies, 760
Spatial requirements
SV40 origin of replication, 91
src gene product
yes gene product common features, 539
Strong-stop (+) DNA
initiation of synthesis
retrovirus reverse transcriptase-associated RNase H, 813
Structural proteins
rubella virus
gene order, 354
Suppressor T cells
HSV-1-induced immune deviation role, 556
Synthetic antigen
herpes simplex virus glycoprotein C antibodies, 430
Synthetic peptides
large-T antigen antibodies, 670

Three-dimensional image analysis
bacteriophage ϕ6 nucleocapsid, 484
Toxins
Pseudomonas exotoxin-epidermal growth factor conjugate, 650
T proteins
polyomavirus
genome construction and functional characterization, 170
Transformation
SV40
large-T antigen–cellular protein p53 complex, 376
Transforming gene
BK virus
DNA rearrangement, 1
yes and *src* gene product common features, 539
Translational discrimination
L-cells, 215
reovirus-infected L-cells, 215
Translational processing
Uukuniemi virus glycoproteins, 806
tRNA-like primers
defective retrovirus particle reverse transcription, 267
Tumors
cottontail rabbit
benign and malignant, viral transcript differences, 706
virus producing and non-virus producing, viral transcript differences, 706
Two-dimensional image analysis
bacteriophage ϕ6 nucleocapsid, 479
Tyrosine-specific protein kinase
Abelson murine leukemia virus
v-*abl* protein *src* homologous region, 223

Uukuniemi virus
glycoprotein G1
translational processing, 806
glycoprotein G2
translational processing, 806
maturation
immunofluorescence microscopy, 137
monoclonal glycoprotein-specific antibodies, 137
UV rescue
mapping phage T4 *bypass31* mutations, 315

v-*abl*
Abelson murine leukemia virus
gene product at cell-substratum contact in transformed cells, 547
v-*abl* protein
carbohydrate-modified, membrane-associated form phosphorylation, 620
kinase activity
src homologous region, 223
L-v-*abl*, 620
membrane-associated, carbohydrate-modified form phosphorylation, 620
phosphorylation, 620
Vaccination
HSV-2
immunity in female genital tract in mice, 747
intravaginal
immunity to HSV-2 in mice, 747
Vaccinia virus
early gene cluster
RNA transcript organization, 283
inteferon treatment
RNA degradation in mouse L cells, 866
late gene
expression regulation, 662
nucleotide sequence, 662
mouse L cells
RNA degradation on interferon treatment, 866
α-27 mutant
replication independent of the host cell nucleus, 359
Valyl-tRNA synthetase
phage T4 restriction, 42

Varicella-zoster virus
fibroblasts, human, 110
polymorphonuclear leukocyte-mediated cytotoxicity, 110
Vesicular stomatitis virus
defective-interfering particle RNA generation
sites of copy choice replication, 515
L gene
mutation frequency, 505
primary structure, 505
L protein
mRNA synthesis in vitro, 628
monoclonal antibodies
protection against infection, 208
mRNA synthesis in vitro
L protein, 628
NS protein, 628
mutation frequency in the polymerase (*L*) gene, 505
NS protein
mRNA synthesis in vitro, 628
nucleocapsid protein
RNA synthesis role, 635
polymerase gene
mutation frequency, 505
primary structure, 505
transcription
ATP dependence, 635
nucleocapsid protein role, 635
v-*fms*
glycoprotein localization, 730
Vibrio cholerae
phage CP-T1
DNA characterization and restriction analysis, 163
Viremia
avian leukosis virus, 123
Visna virus
caprine arthritis-encephalitis virus homology, 713
VX2 carcinoma
cottontail rabbit papillomavirus
genome physical state, 530
transcription, 530
VX7 carcinoma
cottontail rabbit papillomavirus
genome physical state, 530
transcription, 530

Warts
cottontail rabbit papillomavirus
genome physical state, 530
transcription, 530

Xenotropic murine leukemia virus
expression in chemically induced hybrid cells, 876
loci for induction
Bxv-1, 77
Mxv-1, 77

yes gene product
src gene product common features, 539